NCT03984578 is a Phase 2 clinical trial of CAPEOX in Colorectal Cancer, sponsored by National Cancer Centre, Singapore.

Who is sponsoring NCT03984578?

NCT03984578 is sponsored by National Cancer Centre, Singapore.

What drugs are being tested in NCT03984578?

Interventions in NCT03984578: CAPEOX, Pembrolizumab, Capecitabine/ 5-FU, Pembrolizumab, CAPEOX/Pembrolizumab, Pembrolizumab alone, Surgical resection.

What condition does NCT03984578 study?

NCT03984578 studies Colorectal Cancer.

Is NCT03984578 still recruiting?

NCT03984578 is currently completed. Last updated 18 November 2025.

Last reviewed 2025-11-18 · How we verify

NCT03984578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Window of Opportunity Study in Colorectal Cancer

Completed Phase 2 Last updated 18 November 2025

What this trial tests

Phase 2 trial testing CAPEOX in Colorectal Cancer in 33 participants. Completed in 28 February 2025.

Timeline

12 June 2019

Primary endpoint
28 February 2025

28 February 2025

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	12 June 2019
Primary completion	28 February 2025
Estimated completion	28 February 2025
Sites	3 locations across Singapore

Drugs / interventions tested

CAPEOX — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Capecitabine/ 5-FU — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
CAPEOX/Pembrolizumab — full drug profile →
Pembrolizumab alone — full drug profile →
Surgical resection

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 100, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Applications of single-cell sequencing in cancer research: progress and perspectives.
Lei Y, Tang R, Xu J, Wang W, et al · · 2021 · cited 428× · PMID 34108022 · DOI 10.1186/s13045-021-01105-2
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, et al · · 2020 · cited 179× · PMID 32002302 · DOI 10.1080/2162402x.2019.1703449
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.
Huyghe N, Benidovskaya E, Stevens P, Van den Eynde M. · · 2022 · cited 36× · PMID 35565369 · DOI 10.3390/cancers14092241
Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update.
Jung G, Benítez-Ribas D, Sánchez A, Balaguer F. · · 2020 · cited 19× · PMID 33142689 · DOI 10.3390/jcm9113520
Preoperative Strategies for Locally Advanced Colon Cancer.
Nair KG, Kamath SD, Chowattukunnel N, Krishnamurthi SS. · · 2024 · cited 5× · PMID 38349502 · DOI 10.1007/s11864-024-01184-6
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017
Multidimensional decoding of colorectal cancer heterogeneity: Artificial intelligence-enabled precision exploration of single-cell and spatial transcriptomics.
Luan WY, Zhao Q, Zhang Z, Xu ZX, et al · · 2025 · cited 1× · PMID 41114099 · DOI 10.4251/wjgo.v17.i10.110661

Verify or expand the search:

Other trials of CAPEOX

Trials testing the same drug.

NCT06567782 — A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 · Phase 2 · recruiting
NCT05855200 — Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer · Phase 3 · recruiting
NCT06014372 — Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer · Phase 2 · recruiting
NCT06516445 — SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC · Phase 2 · recruiting
NCT03228043 — Apatinib for Resectable Colorectal Cancer · NA · withdrawn

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03984578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
Last refreshed: 18 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03984578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing